| [1] |
Arcaini L, Rossi D, Paulli M. Splenic marginal zone lymphoma: from genetics to management[J]. Blood, 2016, 127(17):2072-2081.
|
| [2] |
Fenske TS, Hamadani M, Cohen JB, et al. Allogeneic hematopoietic cell transplantation as curative therapy for patients with non-Hodgkin lymphoma: increasingly successful application to older patients[J]. Biol Blood Marrow Transplant, 2016, 22(9):1543-1551.
|
| [3] |
Sabattini E, Bacci F, Sagramoso C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview[J]. Pathologica, 2010, 102(3):83-87.
|
| [4] |
Groth CL, Nevel KS, Gwathmey KG, et al. Splenic marginal zone lymphoma: an indolent malignancy leading to the development of neurolymphomatosis[J]. Muscle Nerve, 2017, 55(3):440-444.
|
| [5] |
Kalpadakis C, Pangalis GA, Sachanas S, et al. No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab[J]. Leuk Lymphoma, 2016, 57(11):2705-2708.
|
| [6] |
Kalpadakis C, Pangalis GA, Vassilakopoulos TP, et al. Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?[J]. Leuk Lymphoma, 2014, 55(7):1463-1470.
|
| [7] |
Gujral S, Polampalli SN, Badrinath Y, et al. Immunophenotyping of mature B-cell non Hodgkin lymphoma involving bone marrow and peripheral blood: critical analysis and insights gained at a tertiary care cancer hospital[J]. Leuk Lymphoma, 2009, 50(8):1290-1300.
|
| [8] |
Salido M, Baro C, Oscier D, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group[J]. Blood, 2010, 116(9):1479-1488.
|
| [9] |
Vega F, Cho-Vega JH, Lennon PA, et al. Splenic marginal zone lymphomas are characterized by loss of interstitial regions of chromosome 7q, 7q31.32 and 7q36.2 that include the protection of telomere 1 (POT1) and sonic hedgehog (SHH) genes[J]. Br J Haematol, 2008, 142(2):216-226.
|
| [10] |
阎禹廷，易树华，邱录贵. 脾边缘区淋巴瘤发病机制研究进展[J]. 中华血液学杂志, 2016, 37(4):348-352.
|
| [11] |
Rossi D, Trifonov V, Fangazio M, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development[J]. J Exp Med, 2012, 209(9):1537-1551.
|
| [12] |
Parry M, Rose-Zerilli MJ, Ljungstrom V, et al. Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing[J]. Clin Cancer Res, 2015, 21(18):4174-4183.
|
| [13] |
Piva R, Deaglio S, Fama R, et al. The Kruppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma[J]. Leukemia, 2015, 29(2):503-507.
|
| [14] |
Arribas AJ, Rinaldi A, Mensah AA, et al. DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features[J]. Blood, 2015, 125(12):1922-1931.
|
| [15] |
Starr AG, Caimi PF, Fu P, et al. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era[J]. Hematology, 2017, 22(7):405-411.
|
| [16] |
Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use[J]. Blood, 2006, 107(12):4643-4649.
|
| [17] |
赵征，雷宝霞. 脾边缘区淋巴瘤诊治和预后研究进展[J]. 现代肿瘤医学, 2011, 19(10):2132-2134.
|